WO2001045712A8 - Combinaison de medicaments pour lutter contre des maladies virales - Google Patents

Combinaison de medicaments pour lutter contre des maladies virales

Info

Publication number
WO2001045712A8
WO2001045712A8 PCT/EP2000/012570 EP0012570W WO0145712A8 WO 2001045712 A8 WO2001045712 A8 WO 2001045712A8 EP 0012570 W EP0012570 W EP 0012570W WO 0145712 A8 WO0145712 A8 WO 0145712A8
Authority
WO
WIPO (PCT)
Prior art keywords
combinations
medicaments
viral diseases
treating viral
treating
Prior art date
Application number
PCT/EP2000/012570
Other languages
German (de)
English (en)
Other versions
WO2001045712A1 (fr
Inventor
Arnold Paessens
Karl Deres
Olaf Weber
Erwin Graef
Siegfried Goldmann
Thomas Kraemer
Ulrich Niewoehner
Karl-Heinz Schlemmer
Juergen Stoltefuss
Original Assignee
Bayer Ag
Arnold Paessens
Karl Deres
Olaf Weber
Erwin Graef
Siegfried Goldmann
Thomas Kraemer
Ulrich Niewoehner
Schlemmer Karl Heinz
Juergen Stoltefuss
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1999162010 external-priority patent/DE19962010A1/de
Priority claimed from DE2000112259 external-priority patent/DE10012259A1/de
Application filed by Bayer Ag, Arnold Paessens, Karl Deres, Olaf Weber, Erwin Graef, Siegfried Goldmann, Thomas Kraemer, Ulrich Niewoehner, Schlemmer Karl Heinz, Juergen Stoltefuss filed Critical Bayer Ag
Priority to AU30098/01A priority Critical patent/AU3009801A/en
Publication of WO2001045712A1 publication Critical patent/WO2001045712A1/fr
Publication of WO2001045712A8 publication Critical patent/WO2001045712A8/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des combinaisons de dihydropyrimidines, lamivudine et éventuellement d'interféron, qui inhibent la multiplication de virus HBV, de façon améliorée par rapport aux agents connus.
PCT/EP2000/012570 1999-12-22 2000-12-12 Combinaison de medicaments pour lutter contre des maladies virales WO2001045712A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU30098/01A AU3009801A (en) 1999-12-22 2000-12-12 Combinations of medicaments for treating viral diseases

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19962010.5 1999-12-22
DE1999162010 DE19962010A1 (de) 1999-12-22 1999-12-22 Arzneimittelkombinationen gegen virale Erkrankungen
DE2000112259 DE10012259A1 (de) 2000-03-14 2000-03-14 Arzneimittelkombination gegen virale Erkrankungen
DE10012259.0 2000-03-14

Publications (2)

Publication Number Publication Date
WO2001045712A1 WO2001045712A1 (fr) 2001-06-28
WO2001045712A8 true WO2001045712A8 (fr) 2001-09-13

Family

ID=26004825

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/012570 WO2001045712A1 (fr) 1999-12-22 2000-12-12 Combinaison de medicaments pour lutter contre des maladies virales

Country Status (2)

Country Link
AU (1) AU3009801A (fr)
WO (1) WO2001045712A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2159224E (pt) 2007-06-18 2012-10-24 Sunshine Lake Pharma Co Ltd Tiazolil dihidropirimidinas substituídas com bromo-fenilo
CN104302626B (zh) * 2012-01-06 2016-09-07 爱尔兰詹森科学公司 4,4-二取代的-1,4-二氢嘧啶及其作为治疗乙型肝炎的药物的用途
US20130267517A1 (en) 2012-03-31 2013-10-10 Hoffmann-La Roche Inc. Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
CA2881322A1 (fr) 2012-09-10 2014-03-13 F. Hoffmann-La Roche Ag Heteroaryldihydropyrimidines d'acide 6-amine pour le traitement et la prophylaxie d'une infection par le virus de l'hepatite b
AU2015214096B2 (en) * 2014-02-05 2021-02-11 Novira Therapeutics, Inc. Combination therapy for treatment of HBV infections
CN105153164B (zh) * 2014-05-30 2018-10-30 齐鲁制药有限公司 作为hbv抑制剂的二氢嘧啶并环衍生物
JP6710642B2 (ja) 2014-05-30 2020-06-17 チル ファーマシューティカル カンパニー リミテッド Ｈｂｖ阻害剤としてのジヒドロピリミジン縮環誘導体
BR112018009009A8 (pt) 2015-11-03 2019-02-26 Hoffmann La Roche terapia combinada de um inibidor de formação de capsídeo hbv e um interferon
WO2017108630A1 (fr) * 2015-12-21 2017-06-29 F. Hoffmann-La Roche Ag Polythérapie à inhibiteur hbsag et inhibiteur d'assemblage de capside du vhb
WO2019001420A1 (fr) 2017-06-27 2019-01-03 Janssen Pharmaceutica Nv Dérivés hétéroaryldihydropyrimidine et méthodes de traitement d'infections par le virus de l'hépatite b
CU20200037A7 (es) 2017-11-02 2021-03-11 Aicuris Gmbh & Co Kg Derivados de indol-2-carboxamidas sustituidos con amino-tiazol activos contra el virus de la hepatitis b (vhb)
AR115131A1 (es) 2017-11-02 2020-12-02 Aicuris Gmbh & Co Kg Altamente activas indolo-2-carboxamidas sustituidas con pirazolo-pirimidina activas contra el virus de la hepatitis b (vhb)
AU2019266729A1 (en) * 2018-05-08 2021-03-11 Janssen Sciences Ireland Unlimited Company Dihydropyrimidine derivatives and uses thereof in the treatment of HBV infection or of HBV-induced diseases
US11053235B2 (en) 2018-08-09 2021-07-06 Janssen Sciences Ireland Unlimited Company Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases
WO2020089460A1 (fr) 2018-11-02 2020-05-07 Aicuris Gmbh & Co. Kg Nouvelles urée-6,7-dihydro-4 h-thiazolo[5,4-c]pyridines actives contre le virus de l'hépatite b (vhb)
AR116948A1 (es) 2018-11-02 2021-06-30 Aicuris Gmbh & Co Kg Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (vhb)
UY38434A (es) 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg Nuevas 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activas contra el virus de la hepatitis b (hbv)
AR116947A1 (es) 2018-11-02 2021-06-30 Aicuris Gmbh & Co Kg Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas-indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb)
AR116946A1 (es) 2018-11-02 2021-06-30 Aicuris Gmbh & Co Kg Derivados de urea 6,7-dihidro-4h-pirazolo[4,3-c]piridinas activas contra el virus de la hepatitis b (vhb)
UY38437A (es) 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg Nuevas urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (hbv)
BR112021021580A2 (pt) 2019-04-30 2022-01-04 Aicuris Gmbh & Co Kg Fenil e piridil ureias inovadoras ativas contra o vírus da hepatite b (hbv)
CA3138380A1 (fr) 2019-04-30 2020-11-05 Aicuris Gmbh & Co. Kg Nouvelles oxalyl piperazines actives contre le virus de l'hepatite b (vhb)
AU2020265392A1 (en) 2019-04-30 2021-12-23 Aicuris Gmbh & Co. Kg Novel indolizine-2-carboxamides active against the hepatitis B virus (HBV)
EP3962914A1 (fr) 2019-04-30 2022-03-09 AiCuris GmbH & Co. KG Nouveaux indole-2-carboxamides actifs contre le virus de l'hépatite b (vhb)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5059418A (en) * 1989-09-20 1991-10-22 The Administrators Of The Tulane Educational Fund Synergistic effect of human recombinant interferon-beta on halogenated pyrimidines
AU5923998A (en) * 1997-01-31 1998-08-25 Avid Therapeutics Inc. 2-benzoylamino-3-phenylpropenamide derivatives and methods of using the same
DE19817264A1 (de) * 1998-04-18 1999-10-21 Bayer Ag Neue Dihydropyrimidine
DE19817265A1 (de) * 1998-04-18 1999-10-21 Bayer Ag Verwendung von Dihydropyrimidinen als Arzneimittel und neue Stoffe
DE19817262A1 (de) * 1998-04-18 1999-10-21 Bayer Ag Neue 2-heterocyclisch substituierte Dihydropyrimidine

Also Published As

Publication number Publication date
WO2001045712A1 (fr) 2001-06-28
AU3009801A (en) 2001-07-03

Similar Documents

Publication Publication Date Title
WO2001045712A8 (fr) Combinaison de medicaments pour lutter contre des maladies virales
AU2001248331A1 (en) Medicaments against viral diseases
WO2001077091A3 (fr) Inhibiteurs de polymerases ns5b vhc
WO1999054326A8 (fr) Dihydropyrimidines
WO2004096818A3 (fr) Procede et compositions pour l'identification de composes therapeutiques anti-vih
EP1128832A4 (fr) Composes, compositions et procedes pour traiter des infections virales et les maladies qui y sont liees
PL344223A1 (en) Compositions for the treatment of hiv and other viral infections
AP1782A (en) Use of compounds ?-D or ?-L nucleoside for treating hepatitis C virus.
DK1001801T3 (da) Produkt omfattende mindst en dobbeltkædet RNA kombineret med mindst et interferon til behandling af viral hepatitis
WO2003000200A3 (fr) ss-2'-OU 3'-HALONUCLEOSIDES
WO2004112687A3 (fr) Compositions et methodes antivirales
WO2004028454A3 (fr) 1, 3, 5-triazines destinees au traitement de maladies virales
WO2006033995A3 (fr) Thiazolidine-4-ones possedant une activite antihepatite b
WO2004046159A8 (fr) Derives nucleosidiques antiviraux
WO2001096353A3 (fr) 3'-PROMEDICAMENTS DE 2'-DESOXY-ss-L-NUCLEOSIDES
AU5618501A (en) Dihydropyrimidines and the use thereof as medicaments for the treatment of hepatitis
WO2002006513A3 (fr) Procede de traitement des virus de l'herpes
ZA200306040B (en) Hepatitis B virus treatment.
MXPA02011969A (es) Metodos para el tratamiento de padecimientos virales con il-18 y combinaciones de il-18.
WO2001025239A3 (fr) Oxazinoquinolones utiles pour le traitement d'infections virales
WO2003037265A3 (fr) Methode de traitement d'infections virales
WO2004043402A3 (fr) Nucleosides modifies utilises comme agents antiviraux
WO2004043996A3 (fr) Ligands
BR0108723A (pt) Medicamentos contra doenças viróticas
WO2003090674A3 (fr) Composes, compositions et procedes de traitement ou de prevention d'infections virales et de maladies associees

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WR Later publication of a revised version of an international search report
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP